Select Medical (SEM)
(Delayed Data from NYSE)
$35.36 USD
+0.06 (0.17%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $35.38 +0.02 (0.06%) 7:58 PM ET
5-Strong Sell of 5 5
B Value A Growth F Momentum A VGM
Price, Consensus and EPS Surprise
SEM 35.36 +0.06(0.17%)
Will SEM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SEM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SEM
Select Medical Rises 50.2% YTD: Take Profits or Bet on More Gains?
Select Medical Agrees to Acquire Valir Rehabilitation Hospital
SEM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Select Medical's (SEM) Stock Down 16.9% Despite Q2 Earnings Beat
Select Medical (SEM) Q2 Earnings and Revenues Top Estimates
Q2 Boost for Tenet (THC): A Healthy Dose of Long-Term Gains
Other News for SEM
IHF: Healthcare Dashboard For September
Select Medical to Acquire Oklahoma-based Valir Rehabilitation Hospital
Select Medical to acquire Valir Rehabilitation Hospital, terms not disclosed
What's Driving LifeStance Health Group Inc's Surprising 15% Stock Rally?
Invesco Small Cap Value Fund Q2 2024 Review